| 张丽鹏 李新伟 黄宽军 胡志良 谭新华.DC-CIK细胞免疫治疗晚期结直肠癌患者的远期疗效及其影响因素分析[J].现代生物医学进展英文版,2016,16(22):4348-4351. |
| DC-CIK细胞免疫治疗晚期结直肠癌患者的远期疗效及其影响因素分析 |
| Long-termEffect of DC-CIK Cells Immunology Therapy in Patients withAdvanced Colorectal Cancer |
| |
| DOI： |
| 中文关键词: 晚期结直肠癌 细胞免疫治疗 树突状细胞 细胞因子诱导的杀伤细胞 疗效 |
| 英文关键词: Advanced colorectal cancer Cells immunology therapy Dendritic cells Cytokine induced killer Effect |
| 基金项目: |
|
| Hits: 714 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨树突状细胞（DC）联合细胞因子诱导的杀伤（CIK）细胞免疫治疗晚期结直肠癌（CRC）患者的远期疗效及其影响因
素分析。方法：收集我院2011 年1 月至2014 年1 月收治的112例晚期结直肠癌患者，依据是否接受DC-CIK 细胞免疫治疗将患
者分为对照组（n=47）和观察组（n=65），分别给予一般化疗方案治疗和化疗联合DC-CIK细胞免疫方案治疗，比较两组患者治疗
前后血清肿瘤标志物癌胚抗原（CEA）、淋巴细胞亚群，治疗有效率（RR）、疾病控制率（DCR）、无进展生存期（PFS）和安全性改变，
并分析影响疗效的危险因素。结果：两组治疗后CEA 水平均显著低于治疗前（P<0.05），治疗后对照组CD3+T细胞、CD4+T细胞、
CD8+T细胞和NK 细胞均显著减少（P<0.05），观察组治疗后CD3+T 细胞和CD8+T 细胞数量显著高于治疗前和同期对照组（均
P<0.05）；对照组RR、DCR 和PFS 分别为44.68%、65.96%、6.5 个月，观察组治疗对应指标分别为46.15%、86.15%、9 个月，观察组
DCR 和FPS 均显著高于对照组（P<0.05）；多因素分析发现TNM 分期达到Ⅳ级（P=0.023）和年龄超过60 岁（P=0.006）是影响疗效
的独立危险因素。结论：DC-CIK 细胞免疫治疗晚期结直肠癌安全可靠，能显著改善患者免疫功能控制肿瘤进展，延长生存期，提
高生存质量，值得临床推广。 |
| 英文摘要: |
| Objective:To investigate the long-term effect of dendritic cells (DC) and cytokine induced killer (CIK) cells
immunology therapy of patients with advanced colorectal cancer and its influence factors.Methods:A total of 112 patients with advanced
colorectal cancer (CRC), who were admitted to First People's Hospital of Kashgar region from January 2011 to January 2014, were
collected and divided into control group (n=47) and observation group (n=65) by whether or not accepted DC-CIK cells treatment.The
control group was given general chemotherapy and the observation group, chemotherapy combined with DC-CIK cells. The
carcinoembryonic antigen(CEA), lymphocyte subsets, response rate, disease control rate, progression free survival and security change of
the patients in the two groups before and after treatment were compared; and the risk factors of influencing effect were analyzed.Results:The levels of CEA in the two groups after treatment were significantly lower than before treatment (P<0.05). The CD3+T cells, CD4+T
cells, CD8+T cells and NK cells significantly decreased in the control group after treatment (P<0.05). The number of CD3+T cells and
CD8+T cells in the observation group after treatment was significantly higher than before treatment and control group (p<0.05). The RR,
DCR and PFS of the control group were 44.68%, 65.96% and 6.5 months, the corresponding indicators of the observation group were
46.15%, 86.15%and 9 months; the FPS and DCR of the observation group were significantly higher than those of the control group(P<0.
05). Multivariate analysis showed that grade IV of TNMstage (P=0.023) and aged over 60 (P=0.006) were independent risk factors of
influencing effect.Conclusion:DC-CIK cells immunology therapy is reliable in the treatment of patients with advanced CRC. It can
improve the immune function of patients with tumor progression, prolong the survival time and improve the quality of life, which is
worthy of clinical application. |
|
View Full Text
View/Add Comment Download reader |
| Close |
